Trial Profile
A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2023
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms CAROLINA
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 19 May 2023 Results of pre-specified and post-hoc analyses, we investigated treatment effects on total hypoglycaemic burden in CAROLINA, published in the Diabetes, Obesity and Metabolism
- 07 Nov 2022 Results assessing the associations between hypoglycemia and cardiovascular outcomes from the CARMELINA and CAROLINA trials of the linagliptin, an antihyperglycemic medication, presented at the American Heart Association Scientific Sessions 2022.
- 01 Feb 2022 Results (n=3163) published in the Nutrition, Metabolism and Cardiovascular Diseases